Comparative Study of the Level of Neutralizing Antibodies in People Injecting 4 Types of COVID-19 Vaccine

Abstract

Background: Monitoring the disease of COVID-19 and the effectiveness of prevention and control strategies is considered a public health priority. Therefore, the administration of the COVID-19 vaccine has been approved worldwide. The purpose of this review is to describe the current status and quality of COVID-19 vaccines. Methods: In this study, the history and sampling of people injecting vaccines with different platforms at different ages in one year were done to measure the neutralizing antibody titer by ELISA method. The results were analyzed using the ANOVA method, and the significance level of P < 0.01 was determined. Findings: 168 people (109 women and 59 men) with an average age of 40.4 ± 16 years (minimum 18 and maximum 90) participated in the study. The time between vaccination and sampling was 6.7 ± 6.5 (minimum 0.5 and maximum 32) months. Most participants were in the age groups of 21-30 years, and people aged 81-90 were the minimum in the study. No significant relationship between age and antibody response was observed. Sinopharm vaccine had the highest number of injections (80 people), and Barkat vaccine had the lowest number (13 people). Despite significant differences in average antibody levels, all vaccines effectively produced neutralizing antibodies, and high antibody titers could be measured for a long time. Conclusion: Data on vaccine antibody persistence, including potential booster doses or changes in vaccine formulations, are emphasized. Understanding how these vaccines work in producing protective antibodies is influential in evaluating their effectiveness. © 2024 Isfahan University of Medical Sciences(IUMS). All rights reserved.